Overview

Switching From Restasis to TRYPTYR

Status:
NOT_YET_RECRUITING
Trial end date:
2026-05-15
Target enrollment:
Participant gender:
Summary
Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Restasis at 28 days post-treatment compared to baseline. Dry eye disease (DED) is a prevalent condition that commonly affects patients of working age in addition to the elderly. DED is a complex condition that results in ocular symptoms such as dryness and burning and signs such as decreased tear production (aqueous deficient DED) or increased tear evaporation (evaporative DED). Unfortunately, there is not a perfect correlation between DED signs and symptoms, which makes diagnosis and timely treatment challenging.
Phase:
PHASE4
Details
Lead Sponsor:
Southern College of Optometry